Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) had its target price decreased by Morgan Stanley from $490.00 to $463.00 in a report issued on Thursday morning. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other reports. Leerink Swann reissued a positive rating and issued a $552.00 target price (down from $580.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Robert W. Baird raised Regeneron Pharmaceuticals from an underperform rating to a neutral rating in a research note on Friday, November 3rd. Piper Jaffray Companies reissued an overweight rating and issued a $557.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 10th. Finally, Guggenheim reissued a buy rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $481.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded down $1.67 during mid-day trading on Thursday, reaching $404.54. The company had a trading volume of 771,100 shares, compared to its average volume of 886,192. Regeneron Pharmaceuticals has a 12-month low of $340.09 and a 12-month high of $543.55. The firm has a market cap of $43,346.87, a PE ratio of 35.03, a price-to-earnings-growth ratio of 1.39 and a beta of 1.56. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same period last year, the firm posted $3.13 EPS. The business’s revenue was up 23.0% on a year-over-year basis. equities research analysts forecast that Regeneron Pharmaceuticals will post 13.77 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This story was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dailypolitical.com/2017/11/12/regeneron-pharmaceuticals-inc-regn-given-new-463-00-price-target-at-morgan-stanley.html.

In related news, Chairman P Roy Vagelos sold 15,191 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $470.15, for a total value of $7,142,048.65. Following the completion of the sale, the chairman now directly owns 329,543 shares in the company, valued at $154,934,641.45. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The disclosure for this sale can be found here. Insiders sold 88,942 shares of company stock worth $42,064,076 in the last ninety days. 10.80% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.3% in the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after buying an additional 416,192 shares during the period. BlackRock Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.7% in the second quarter. BlackRock Inc. now owns 6,188,267 shares of the biopharmaceutical company’s stock valued at $3,039,305,000 after buying an additional 41,406 shares during the period. Vanguard Group Inc. lifted its stake in Regeneron Pharmaceuticals by 2.9% during the second quarter. Vanguard Group Inc. now owns 5,270,458 shares of the biopharmaceutical company’s stock worth $2,588,533,000 after purchasing an additional 148,962 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in Regeneron Pharmaceuticals by 1.5% during the second quarter. Artisan Partners Limited Partnership now owns 1,962,480 shares of the biopharmaceutical company’s stock worth $963,852,000 after purchasing an additional 29,252 shares during the last quarter. Finally, Polen Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 7.3% during the second quarter. Polen Capital Management LLC now owns 1,586,320 shares of the biopharmaceutical company’s stock worth $779,105,000 after purchasing an additional 108,413 shares during the last quarter. Institutional investors and hedge funds own 67.63% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.